An international team of researchers led by Dr. Eleanor Fish, Scientist Emeritus at the Toronto General Hospital Research Institute, UHN, and professor in the University of Toronto‘s Department of Immunology, has shown for the first time that an antiviral drug can help speed up the recovery of COVID-19 patients.
According to the new study, published Friday in Frontiers in Immunology, treatment with interferon(IFN)- a2b may significantly accelerate virus clearance and reduce levels of inflammatory proteins in COVID-19 patients.
The research team found that treatment with this drug, which has been used clinically for many years, significantly reduced the duration of detectable virus in the upper respiratory tract, on average by about seven days. It also reduced blood levels of interleukin(IL)-6 and C-reactive protein (CRP), two inflammatory proteins found in COVID-19 patients.
Dr. Fish says the research team considered IFN-a therapy for COVID-19 after they demonstrated interferon provided therapeutic benefit during the SARS outbreak of 2002 and 2003.
“Rather than developing a virus-specific antiviral for each new virus outbreak, I would argue that we should consider interferons as the ‘first responders’ in terms of treatment,” says Dr. Fish.
“Interferons have been approved for clinical use for many years, so the strategy would be to ‘repurpose’ them for severe acute virus infections.”
Boosting a natural defence mechanism
Interferons are a group of signaling proteins released by the human body in response to all viruses. As Dr. Fish explains, they are a “first line of defence.”
They target different stages of a virus’s life cycle, inhibiting them from multiplying. They also boost an immune response by activating different immune cells to clear an infection. Some viruses, however, can block this natural defense mechanism.
“But it is possible to override this block. If a virus blocks interferon production, then treating with interferon can offset this.”
The researchers conducted this exploratory study on a group of 77 patients with COVID-19 in Wuhan, China. These patients were admitted to Union Hospital, Tongii Medical College, between January 16 and February 20, 2020. They represented moderate cases of the disease as none of the patients required intensive care or prolonged oxygen supplementation or intubation.
Despite the study’s limitations of a small, non-randomized group of patients, the work provides several important and novel insights into COVID-19 disease, notably that treatment with IFN-a2b can accelerate viral clearance from the upper respiratory tract and also reduce circulating levels of inflammatory factors that are associated with severe COVID-19.
Dr. Fish says a randomized clinical trial is a crucial next step. According to her, a clinical trial with a larger group of infected patients who are randomized to treatment or placebo would further this research.
In the meantime, the findings from this study are the first to suggest therapeutic efficacy of IFN-a2b as an available antiviral intervention for COVID-19, which may also benefit public health measures by shortening the duration of viral clearance and therefore slowing the tide of the pandemic.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Recovery of COVID-19 patients
- COVID-19 may cause loss of brain tissue; Delta variant fuels steep infection rise in Englandon June 18, 2021 at 11:29 am
The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus. COVID-19 ...
- These communities remain at high risk for dangerous Covid-19 variants rapidly increasing in US, expert warnson June 18, 2021 at 10:53 am
The Delta variant, a form of Covid-19 first identified in India, has increased to approximately 10% of coronavirus cases in the United States.
- Losartan found ineffective in reducing hospitalization from mild COVID-19on June 18, 2021 at 10:37 am
University of Minnesota Medical School researchers determined that the common blood pressure medication, losartan, is not effective in reducing hospitalization for mildly-ill COVID-19 outpatients.
- 796 test Covid-19 positive as 328 recoveron June 18, 2021 at 8:17 am
Some 796 people have tested positive for the coronavirus today, the highest number this month, from a 7,392 sample size conducted in the last 24 hours. Health Cabinet Secretary Mutahi Kagwe (pictured) ...
- Covid-19: Three new cases, four patients recoveron June 18, 2021 at 3:33 am
Three new Covid-19 cases were recorded on Friday, while four patients have recovered, health authorities said.
Go deeper with Google Headlines on:
Recovery of COVID-19 patients
Go deeper with Bing News on:
- U.S. to invest over 3 billion USD for COVID-19 antiviral medicineson June 18, 2021 at 12:00 pm
The US government is investing more than 3 billion US dollars to accelerate the development and manufacturing of antiviral m ...
- Biden administration to invest $3 billion for Covid-19 antiviral medicineson June 18, 2021 at 10:21 am
The Biden administration on Thursday announced it would invest more than $3 billion from the American Rescue Plan to accelerate the discovery, development and manufacturing of Covid-19 antiviral medic ...
- Biden Administration Infuses $3.2 Billion Into Antiviral Developmenton June 18, 2021 at 10:11 am
A new federal program aims to speed up the development and manufacturing of medicines to manage viruses. A pill to treat covid, which could be taken at home and in early stages of the disease, is ...
- RIG-1 agonist shows potent antiviral efficacy against SARS-CoV-2 infectionon June 18, 2021 at 8:57 am
A team of scientists from the United States has recently revealed the antiviral efficacy of stem-loop RNA 14, a RIG-1 agonist, in controlling severe acute respiratory syndrome coronavirus 2 ...
- Biden Administration invests $3 billion from ARP as part of COVID-19 antiviral development strategyon June 18, 2021 at 8:52 am
The intent is to respond to the urgent need for antivirals by spurring the availability of medicines to prevent serious illness.